[1]郭俊林 顾永林 彭勇.氟喹诺酮类药物增加主动脉瘤和夹层风险的研究进展[J].心血管病学进展,2023,(2):155-157,162.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.013]
 GUO Junlin,GU Yonglin,PENG Yong.Fluoroquinolones Increased Risk of Aortic Aneurysm and Dissection[J].Advances in Cardiovascular Diseases,2023,(2):155-157,162.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.013]
点击复制

氟喹诺酮类药物增加主动脉瘤和夹层风险的研究进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年2期
页码:
155-157,162
栏目:
综述
出版日期:
2023-02-25

文章信息/Info

Title:
Fluoroquinolones Increased Risk of Aortic Aneurysm and Dissection
作者:
郭俊林1 顾永林1 彭勇2
 (1.四川省广安市人民医院心内科/四川大学华西广安医院,四川 广安 638000; 2.四川大学华西医院心内科,四川 成都 610041)
Author(s):
GUO Junlin1GU Yonglin1PENG Yong2
Department of Cardiology,Guang’an People’s Hospital/West China Guang’an Hospital, Sichuan University,Guang’an 638000, Sichuan,China;2.Department of Cardiology,West China Hospital of Sichuan University,Chengdu 610041, Sichuan,China)
关键词:
主动脉瘤主动脉夹层氟喹诺酮类药物
Keywords:
Aortic aneurysm Aortic dissection Fluoroquinolones
DOI:
10.16806/j.cnki.issn.1004-3934.2023.02.013
摘要:
主动脉瘤(AA)和主动脉夹层(AD)是威胁生命健康的主要疾病。氟喹诺酮类抗生素(FQ)具有重要的临床用途和广泛的抗菌谱。FQ可导致主动脉血管破裂风险增加。FQ诱导的AA/AD的确切机制目前尚不十分清楚。现讨论FQ与AA/AD之间相关性的最新研究进展。
Abstract:
Aortic aneurysm(AA) and aortic dissection (AD) are major life-threatening diseases around the world. Fluoroquinolones (FQ) remain one of the most important kind of antibiotics and have a wider clinical use and broad antibacterial spectrum. FQ was warned about an increased risk of ruptures in the aorta blood vessel in certain patients. The exact mechanism of FQ-induced AA/AD remains unclear. This review aims to the latest research progress of the alarming association between FQ and AA/AD. 

参考文献/References:

[1]Newton ER,Akerman AW,Strassle PD,et al. Association of fluoroquinolone use with short-term risk of development of aortic aneurysm[J]. JAMA Surg,2021,156(3):264-272.

[2]张波,王文艳,陈蒙华. 氟喹诺酮抗生素与主动脉瘤/夹层发生和发展的关系[J]. 临床心血管病杂志,2020,36(12):1083-1087.

[3]管玉瑶,刘雪梅,杨静,等. 某院氟喹诺酮类注射液高风险因素人群用药安全性分析[J]. 药物流行病学杂志,2020,29(10):666-669.

[4]Pasternak B,Inghammar M,Svanstr?m H,et al. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study[J]. BMJ,2018,360:k678.

[5]Lee CC,Lee MG,Hsieh R,et al. Oral fluoroquinolone and the risk of aortic dissection[J]. J Am Coll Cardiol,2018,72(12):1369-1378.

[6]Sidloff D,Choke E,Stather P,et al. Mortality from thoracic aortic diseases and associations with cardiovascular risk factors[J]. Circulation,2014,130(25):2287-2294.

[7]Schmitz-Rixen T,Keese M,Hakimi M,et al. Ruptured abdominal aortic aneurysm epidemiology,predisposing factors,and biology[J]. Langenbecks Arch Surg,2016,401(3):275-288.

[8]Ezelarab HAA,Abbas SH,Hassan HA,et al. Recent updates of fluoroquinolones as antibacterial agents[J]. Arch Pharm,2018,351(9):e1800141.

[9] Jun C,Fang B. Current progress of fluoroquinolones-increased risk of aortic aneurysm and dissection[J]. BMC Cardiovasc Disord,2021,21(1):470.

[10]Zhang GF,Zhang S,Pan B,et al. 4-Quinolone derivatives and their activities against Gram positive pathogens[J]. Eur J Med Chem,2018,1(143):710-723.

[11]Zhang GF,Liu X,Zhang S,et al. Ciprofloxacin derivatives and their antibacterial activities[J]. Eur J Med Chem,2018,25(146):599-612.

[12]Kuula LSM,Viljemaa KM,Backman JT,et al. Fluoroquinolone-related adverse events resulting in health service use and costs:a systematic review[J]. PLoS One,2019,14(4):e0216029.

[13]Noman AT,Qazi AH,Alqasrawi M,et al. Fluoroquinolones and the risk of aortopathy:a systematic review and meta-analysis[J]. Int J Cardiol,2019:1(274):299-302.

[14]Lee CC,Lee MT,Chen YS,et al. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone[J]. JAMA Intern Med,2015,175(11):1839-1847.

[15]Daneman N,Lu H,Redelmeier DA,et al. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study[J]. BMJ Open,2015,5(11):e010077.

[16] Latif A,Ahsan MJ,Kapoor V,et al. Fluoroquinolones and the risk of aortopathy:a systematic review and meta-analysis[J]. WMJ,2020,119(3):185-189.

[17]Frankel WC,Trautner BW,Spiegelman A,et al. Patients at risk for aortic rupture often exposed to fluoroquinolones during hospitalization[J]. Antimicrob Agents Chemother,2019,63(2):e01712-18.

[18]Howard DP,Banerjee A,Fairhead JF,et al. Age-specific incidence,risk factors and outcome of acute abdominal aortic aneurysms in a defined population[J]. Br J Surg,2015,102(8):907-915.

[19]Dolladille C,Chrétien B,Sassier M,et al. Fluoroquinolone and aortic dissection:is it a class effect[J]. J Am Coll Cardiol,2019,73(3):382-383.

[20]LeMaire SA,Zhang L,Luo W,et al. Effect of ciprofloxacin on susceptibility to aortic dissection and rupture in mice[J]. JAMA Surg,2018,153(9):e181804.

[21]Ogino H,Fujii M,Ono M,et al. In vivo and in vitro effects of fluoroquinolones on lipopolysaccharide-induced pro-inflammatory cytokine production[J]. J Infect Chemother,2009,15(3):168-173.

[22]Bouissou C, Lacolley P, Dabire H,et al. Increased stiffness and cell-matrix interactions of abdominal aorta in two experimental nonhypertensive models:long-term chemically sympathectomized and sinoaortic denervated rats[J]. J Hypertens,2014,32(3):652-658.

[23]Rodríguez-Carrio J, Cerro-Pardo I, Lindholt JS,et al. Malondialdehyde-modified HDL particles elicit a specific IgG response in abdominal aortic aneurysm[J]. Free Radic Biol Med,2021,174:171-181.

[24]Hadi T,Boytard L,Silvestro M,et al. Macrophage-derived netrin-1 promotes abdominal aortic aneurysm formation by activating MMP3 in vascular smooth muscle cells[J]. Nat Commun,2018,9(1):5022.

[25]Guzzardi DG, Teng G, Kang S,et al. Induction of human aortic myofibroblast-mediated extracellular matrix dysregulation:a potential mechanism of fluoroquinolone-associated aortopathy[J] . J Thorac Cardiovasc Surg,2019,157(1):109-119.e2.

[26]Son N,Choi E,Chung SY,et al. Risk of aortic aneurysm and aortic dissection with the use of fluoroquinolones in Korea: a nested case-control study[J]. BMC Cardiovasc Disord,2022,22(1):44.

[27]Chen YY,Yang SF,Yeh HW,et al. Association between aortic aneurysm and aortic dissection with fluoroquinolones use in patients with urinary tract infections:a population-based cohort study[J]. J Am Heart Assoc,2022,11(6):e023267.

[28]Smart DJ, Halicka HD, Traganos F,et al. Ciprofloxacin-induced G2 arrest and apoptosis in TK6 lymphoblastoid cells is not dependent on DNA double-strand break formation[J]. Cancer Biol Ther,2008,7(1):113-119.

[29]Pommicr Y,Sun Y,Huang SN,et al. Roles of eukaryotic topoisomerases in transcription,replication and genomic stability[J]. Nat Rev Mol Cell Biol,2016:17(11):703-721.

[30]Lim EJ, Yoon YJ, Heo J,et al. Ciprofloxacin enhances TRAIL-induced apoptosis in lung cancer cells by upregulating the expression and protein stability of death receptors through CHOP expression[J]. Int J Mol Sci,2018,19(10):3187.

相似文献/References:

[1]肖秋蓓 王志维.急性主动脉夹层并发急性肺损伤研究进展[J].心血管病学进展,2020,(12):1260.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.009]
 XIAO QiubeiWANG Zhiwei.Acute Aortic Dissection Complicated with Acute Lung Injury[J].Advances in Cardiovascular Diseases,2020,(2):1260.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.009]
[2]夏平.“8+2”心电图临床价值的研究进展夏平[J].心血管病学进展,2021,(9):800.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2021.09.009]
 XIA Ping.Clinical Value of 8 Plus 2 ECG[J].Advances in Cardiovascular Diseases,2021,(2):800.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2021.09.009]
[3]蔡宇宸 姚弈伟 陈鑫.ADAMTS家族蛋白与主动脉瘤相关性的研究及进展[J].心血管病学进展,2022,(5):450.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.016]
 CAI Yuchen,YAO Yiwei,CHEN Xin.The Association of ADAMTS Family with Aortic Aneurysms[J].Advances in Cardiovascular Diseases,2022,(2):450.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.016]
[4]孙阳雪 郭宏.肾囊肿与主动脉瘤相关性病因学研究进展[J].心血管病学进展,2022,(9):808.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.010]
 SUN Yangxue,GUO Hongwei.Association Between Renal Cyst and Aortic Aneurysm[J].Advances in Cardiovascular Diseases,2022,(2):808.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.010]
[5]李旭 王志维.CTRP2与主动脉夹层发生的相关性研究[J].心血管病学进展,2024,(5):476.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.020]
 LI Xu,WANG Zhiwei.Correlation Between CTRP2 and the Occurrence of Aortic Dissection[J].Advances in Cardiovascular Diseases,2024,(2):476.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.020]
[6]温欢 张琼阁 刘金波 王宏宇,7.主动脉夹层临床早期评价技术最新进展[J].心血管病学进展,2024,(8):707.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.008]
 WEN Huan,ZHANG Qiongge,LIU Jinbo,et al.Early Clinical Evaluation Techniques for Aortic Dissection[J].Advances in Cardiovascular Diseases,2024,(2):707.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.008]
[7]黄延鑫 姚园 吴星亮 刘力源 易欣.血管平滑肌细胞程序性死亡在主动脉夹层中的研究进展与展望[J].心血管病学进展,2024,(8):712.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.009]
 HUANG YanxinYAO YuanWU XingliangLIU LiyuanYI Xin.Progress and Perspectives of Programmed Vascular Smooth Muscle Cell Death?n Aortic Coarctation[J].Advances in Cardiovascular Diseases,2024,(2):712.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.009]

更新日期/Last Update: 2023-03-23